LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Seattle Genetics to be a specialty pharmacy partner for TUKYSA™ (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.
“The approval of TUKYSA for patients with HER2-positive metastatic breast cancer is an important advancement in fighting this devastating disease,” said Paul Jardina, President and CEO, Onco360. “As a specialty pharmacy dedicated to serving people with cancer, Onco360 is honored to be selected as a distribution partner for TUKYSA. We are committed to improving the lives of patients suffering from HER2-positive metastatic breast cancer.”
According to the National Cancer Institute (NCI), approximately 276,480 patients are diagnosed with breast cancer annually, with corresponding 42,170 deaths. The five-year overall survival for breast cancer, regardless of stage, is 90%. Approximately 20% of breast cancer patients are found to be HER2-positive, an aggressive histological subtype of breast cancer. Unfortunately, about 25-30% of patients with HER2-positive breast cancer experience disease recurrence with metastatic disease.
TUKYSA is manufactured by Seattle Genetics, an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer. The FDA’s approval of TUKYSA in combination with capecitabine and trastuzumab is based on the results of the Phase II HER2CLIMB clinical trial, which demonstrated a 34% improvement in overall survival for the triplet regimen compared to capecitabine + trastuzumab doublet therapy. For full prescribing information, visit TUKYSA.com.
Community and hospital-based oncologists can immediately place prescription orders with Onco360 for TUKYSA, as well as other cancer and supportive care medications, including capecitabine and trastuzumab. Referral forms and information on how to order can be found at Onco360.com/Order.
About Onco360® Oncology Pharmacy:
Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC- and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.
